CRISPR Gene Editing in Lipid Disorders and Atherosclerosis: Mechanisms and Opportunities

Drucebo effect – the challenge we should all definitely face!

(2021) Maciej Banach et al.   Archives of Medical Science

Lipid-lowering therapies: Better together

(2021) Maciej Banach et al.   ATHEROSCLEROSIS

Pooled Patient-Level Analysis of Inclisiran Trials in Patients With Familial Hypercholesterolemia or Atherosclerosis

(2021) R. Scott Wright et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Long-term stable reduction of low-density lipoprotein in nonhuman primates following in vivo genome editing of PCSK9

(2021) Lili Wang et al.   MOLECULAR THERAPY

In vivo CRISPR base editing of PCSK9 durably lowers cholesterol in primates

(2021) Kiran Musunuru et al.   NATURE

Optimal use of lipid-lowering therapy after acute coronary syndromes: A Position Paper endorsed by the International Lipid Expert Panel (ILEP)

(2021) Maciej Banach et al.   PHARMACOLOGICAL RESEARCH

Risk-factors associated with extremely high cardiovascular risk of mid- and long-term mortality following myocardial infarction: Analysis of the Hyperlipidaemia Therapy in tERtiary Cardiological cEnTer (TERCET) registry

(2021) Krzysztof Dyrbuś et al.   ATHEROSCLEROSIS

RNA Silencing in the Management of Dyslipidemias

(2021) Neil C. Henney et al.   Current Atherosclerosis Reports

Nocebo/drucebo effect in statin-intolerant patients: an attempt at recommendations

(2021) Peter E Penson et al.   EUROPEAN HEART JOURNAL

PCSK9 vaccine: so near, yet so far!

(2021) Amirhossein Sahebkar et al.   EUROPEAN HEART JOURNAL

Construct design for CRISPR/Cas-based genome editing in plants

(2021) Md Mahmudul Hassan et al.   TRENDS IN PLANT SCIENCE

In vivo delivery of CRISPR-Cas9 therapeutics: Progress and challenges

(2021) Matthew Behr et al.   Acta Pharmaceutica Sinica B

Extreme cardiovascular risk—do we need a new risk category?

(2021) Krzysztof Dyrbuś et al.   EUROPEAN HEART JOURNAL

The prevalence of statin intolerance worldwide: a systematic review and meta-analysis with 4,143,517 patients

(2021) I Bytyci et al.   EUROPEAN HEART JOURNAL

Inclisiran: a small interfering RNA strategy targeting PCSK9 to treat hypercholesterolemia

(2021) Yajnavalka Banerjee et al.   Expert Opinion On Drug Safety

Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel

(2020) Jan Borén et al.   EUROPEAN HEART JOURNAL

CRISPR treatment inserted directly into the body for first time

(2020) Heidi Ledford   NATURE

What do we know about the role of lipoprotein(a) in atherogenesis 57 years after its discovery?

(2020) Barbara Cybulska et al.   PROGRESS IN CARDIOVASCULAR DISEASES

CRISPR Gene Therapy: Applications, Limitations, and Implications for the Future

(2020) Fathema Uddin et al.   Frontiers in Oncology

LDL-C: lower is better for longer—even at low risk

(2020) Peter E. Penson et al.   BMC Medicine

Inactivation of Apoc3 by CRISPR/Cas9 Protects Against Atherosclerosis in Hamsters

(2020) Mengmeng Guo et al.   CIRCULATION RESEARCH

Pioneers of revolutionary CRISPR gene editing win chemistry Nobel

(2020) Heidi Ledford et al.   NATURE

Various Aspects of a Gene Editing System—CRISPR–Cas9

(2020) Edyta Janik et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

How much should LDL cholesterol be lowered in secondary prevention? Clinical efficacy and safety in the era of PCSK9 inhibitors

(2020) Barbara Cybulska et al.   PROGRESS IN CARDIOVASCULAR DISEASES

Statins and LDL-C in Secondary Prevention—So Much Progress, So Far to Go

(2020) Maciej Banach et al.   JAMA Network Open

Viral Delivery Systems for CRISPR

(2019) Christine Xu et al.   Viruses-Basel

Methodologies for Improving HDR Efficiency

(2019) Mingjie Liu et al.   Frontiers in Genetics

CRISPR

(2019) Mia Furgurson et al.   CURRENT OPINION IN LIPIDOLOGY

Delivery Aspects of CRISPR/Cas for in Vivo Genome Editing

(2019) Danny Wilbie et al.   ACCOUNTS OF CHEMICAL RESEARCH

The Cas4-Cas1-Cas2 complex mediates precise prespacer processing during CRISPR adaptation

(2019) Hayun Lee et al.   eLife

CRISPR repeat sequences and relative spacing specify DNA integration by Pyrococcus furiosus Cas1 and Cas2

(2019) Julie Grainy et al.   NUCLEIC ACIDS RESEARCH

P705Step by step diagnosis and management of statin intolerance: position paper from an international lipid expert panel

(2019) P Penson et al.   EUROPEAN HEART JOURNAL

Inclisiran—New hope in the management of lipid disorders?

(2019) Krzysztof Dyrbuś et al.   Journal of Clinical Lipidology

Therapeutic effect of nanoliposomal PCSK9 vaccine in a mouse model of atherosclerosis

(2019) Amir Abbas Momtazi-Borojeni et al.   BMC Medicine

Hyperlipidemia induces typical atherosclerosis development in Ldlr and Apoe deficient rats

(2018) Yongliang Zhao et al.   ATHEROSCLEROSIS

The Biology of CRISPR-Cas: Backward and Forward

(2018) Frank Hille et al.   CELL

Delivering CRISPR: a review of the challenges and approaches

(2018) Christopher A. Lino et al.   DRUG DELIVERY

The Role of Nutraceuticals in Statin Intolerant Patients

(2018) Maciej Banach et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Cas4 Nucleases Define the PAM, Length, and Orientation of DNA Fragments Integrated at CRISPR Loci

(2018) Masami Shiimori et al.   MOLECULAR CELL

A Single Administration of CRISPR/Cas9 Lipid Nanoparticles Achieves Robust and Persistent In Vivo Genome Editing

(2018) Jonathan D. Finn et al.   Cell Reports

Comparison of Various Nuclear Localization Signal-Fused Cas9 Proteins and Cas9 mRNA for Genome Editing in Zebrafish

(2018) Peinan Hu et al.   G3-Genes Genomes Genetics

Novel Epigenetic Techniques Provided by the CRISPR/Cas9 System

(2018) Nina Xie et al.   Stem Cells International

PAM identification by CRISPR-Cas effector complexes: diversified mechanisms and structures

(2018) Daniel Gleditzsch et al.   RNA Biology

What have we learned about lipids and cardiovascular risk from PCSK9 inhibitor outcomes trials?

(2018) Maciej Banach et al.   CARDIOVASCULAR RESEARCH

Attenuation of Microbiotal Dysbiosis and Hypertension in a CRISPR/Cas9 Gene Ablation Rat Model of GPER1

(2018) Harshal Waghulde et al.   HYPERTENSION

Introducing the ‘Drucebo’ effect in statin therapy: a systematic review of studies comparing reported rates of statin-associated muscle symptoms, under blinded and open-label conditions

(2018) Peter E. Penson et al.   Journal of Cachexia Sarcopenia and Muscle

Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel

(2017) Brian A. Ference et al.   EUROPEAN HEART JOURNAL

Statin Intolerance and Risk of Coronary Heart Events and All-Cause Mortality Following Myocardial Infarction

(2017) Maria-Corina Serban et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol

(2017) Kausik K. Ray et al.   NEW ENGLAND JOURNAL OF MEDICINE

Genetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease

(2017) Frederick E. Dewey et al.   NEW ENGLAND JOURNAL OF MEDICINE

CRISPR/Cas9-mediated ApoE-/- and LDLR-/- double gene knockout in pigs elevates serum LDL-C and TC levels

(2017) Lei Huang et al.   Oncotarget

Profiling single-guide RNA specificity reveals a mismatch sensitive core sequence

(2017) Ting Zheng et al.   Scientific Reports

Targeting PCSK9 for therapeutic gains: Have we addressed all the concerns?

(2016) Yajnavalka Banerjee et al.   ATHEROSCLEROSIS

Genome editing with CRISPR/Cas9 in postnatal mice corrects PRKAG2 cardiac syndrome

(2016) Chang Xie et al.   CELL RESEARCH

A Precision Medicine Approach to the Rescue of Function on Malignant Calmodulinopathic Long-QT SyndromeNovelty and Significance

(2016) Worawan B. Limpitikul et al.   CIRCULATION RESEARCH

Interpretation of the evidence for the efficacy and safety of statin therapy

(2016) Rory Collins et al.   LANCET

Defining and improving the genome-wide specificities of CRISPR–Cas9 nucleases

(2016) Shengdar Q. Tsai et al.   NATURE REVIEWS GENETICS

CRISPR-Cas9 for in vivo Gene Therapy: Promise and Hurdles

(2016) Wei-Jing Dai et al.   Molecular Therapy-Nucleic Acids

The CRISPR-Cas immune system: Biology, mechanisms and applications

(2015) Devashish Rath et al.   BIOCHIMIE

Statin intolerance – an attempt at a unified definition. Position paper from an International Lipid Expert Panel

(2015) Maciej Banach et al.   Expert Opinion On Drug Safety

Crystal Structure of Cas9 in Complex with Guide RNA and Target DNA

(2014) Hiroshi Nishimasu et al.   CELL

Expanding the genetic editing tool kit: ZFNs, TALENs, and CRISPR-Cas9

(2014) Rajat M. Gupta et al.   JOURNAL OF CLINICAL INVESTIGATION

Loss-of-Function Mutations in APOC3, Triglycerides, and Coronary Disease

(2014)   NEW ENGLAND JOURNAL OF MEDICINE

PCSK9 Inhibition - A Novel Mechanism to Treat Lipid Disorders?

(2013) Maciej Banach et al.   CURRENT PHARMACEUTICAL DESIGN

Function and Regulation of Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) / CRISPR Associated (Cas) Systems

(2012) Corinna Richter et al.   Viruses-Basel

CRISPR RNA maturation by trans-encoded small RNA and host factor RNase III

(2011) Elitza Deltcheva et al.   NATURE

The CRISPR System: Small RNA-Guided Defense in Bacteria and Archaea

(2010) Fedor V. Karginov et al.   MOLECULAR CELL

Mutations and polymorphisms in the proprotein convertase subtilisin kexin 9 (PCSK9) gene in cholesterol metabolism and disease

(2009) Marianne Abifadel et al.   HUMAN MUTATION